A look at the breast cancer data for 3 rising early stage compounds
A rapid evolving field creates challenges for those following the leaders since the SOC can change quickly
When resistance and toxicities collide, the inevitable fallout is more likely
What's looking interesting in early stage trials at ASCO24?
Some up and coming novel ADCs to watch out for
